Ovarian Cancer

PTEN tumor suppressor gene enhances cellular response to cancer agents

Published in Gene Therapy Weekly, June 27th, 2002

by Sonia Nichols, senior medical writer - Medical investigators have now discerned how PTEN gene expression might sensitize ovarian cancer cells to a metabolite of the chemotherapy irinotecan, which is a topoisomerase I inhibitor.

"PTEN is a tumor suppressor gene that was identified on chromosome 10q23. In addition to its original function as a tumor suppressor, this gene product was recently reported to enhance the sensitivity of cancer cells to anticancer agents," described Yasushi Saga and coauthors, Jichi Medical School, Tochigi, Japan, in the journal Clinical Cancer Research.

By introducing cDNA from this gene into an ovarian cancer cell...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-06-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry